Screener
Syndax Pharmaceuticals SNDX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Selling, general and administrative | 37,588 | 41,031 |
| Collaboration loss | — | 247 |
| Total operating expenses | 99,066 | 103,799 |
| Loss from operations | (34,202) | (83,757) |
| Other (expense) income, net: | ||
| Royalty interest expense | (11,846) | (8,049) |
| Other interest expense | — | (2) |
| Interest income | 3,561 | 7,183 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's operating income?
- Syndax Pharmaceuticals (SNDX) reported operating income of -$34.2M in Q1 2026.
- How has Syndax Pharmaceuticals's operating income changed year-over-year?
- Syndax Pharmaceuticals's operating income increased by 59.2% year-over-year, from -$83.76M to -$34.2M.
- What is the long-term trend for Syndax Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's operating income has grown at a 79.6% compound annual growth rate (CAGR), from $26.22M to -$273.08M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Syndax Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude